Vyxeos Liposomal Delivers
Quadruple Endpoint Superiority vs DA 3+71

mOS

9.56 vs 5.95 months,
HR 0.69 (95% CI 0.52, 0.90); p=0.003

post-
HSCT
mOS

NR vs 10.25 months;
HR 0.46 (95% CI 0.24, 0.89); p=0.009

CR/CRi

48% vs 33%;
p=0.016

EFS

2.53 vs 1.31 months;
HR 0.74 (95% CI, 0.58, 0.96); p=0.021

Similar safety profile with prolonged myelosuppression vs. DA 3+72,3

Discover more View references and abbreviations
UK-VYX-2200065 | July 2022
Close

ABBREVIATIONS
CI, confidence interval; CR/CRi, complete remission/complete remission with incomplete haematological recovery; DA, daunorubicin and cytarabine; EFS, event-free survival; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; mOS, median overall survival; NR, not reached

REFERENCES
1. Lancet JE, et al. J Clin Oncol 2018;36(26):2684–2692
2. Lancet JE, et al. E-poster EP556. EHA25 Virtual Congress 2020
3. Vyxeos Liposomal Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9442/smpc

Insights From BSH ‘22

Watch the latest KOL interviews discussing decision-making factors in AML

Discover more View abbreviations
UK-VYX-2200066 | June 2022
Close

ABBREVIATIONS
AML, acute myeloid leukaemia; BSH, British Society for Haematology; KOL, key opinion leader

Vyxeos Liposomal is the
first dual-drug advanced liposomal formulation of DA1

Discover more View references and abbreviations
UK-VYX-2200067 | June 2022
Close

Abbreviations
DA, daunorubicin and cytarabine

REFERENCES
1. Tolcher AW, Mayer LD. Future Oncol 2018;14(13):1317–1332

Explore Highlights in AML

Discover the significance of cytogenetics in managing AML-MRC and t-AML

Discover more

Uncover the impact of Vyxeos Liposomal in AML-MRC and t-AML patients from four European real-world studies

Discover more

Discover resources for the treatment of AML-MRC and t-AML

Discover more
AML-MRC and t-AML Patients Have Poorer Outcomes
Compared to de novo AML Patients1

Over 1 in 4 patients with AML fall within these high-risk categories:1

Zoom
new_updated_pie_chart-01

Survival by AML subset treated with intensive chemotherapy:1

Zoom
new_updated_KM_Graph-01

Patients with therapy-related or secondary AML† have particularly poor outcomes:

  • When treated intensively, t-AML and sAML have decreased remission rates and survival compared with de novo AML1
  • The increasing use of adjuvant cancer therapies and improved cancer survivorship mean that the incidence of t-AML is rising1
Vyxeos Liposomal Delivers
Quadruple Endpoint Superiority vs DA 3+72
mOS

9.56 vs 5.95 months,
HR 0.69 (95% CI 0.52, 0.90); p=0.003

post-
HSCT
mOS

NR vs 10.25 months;
HR 0.46 (95% CI 0.24, 0.89); p=0.009

CR/CRi

48% vs 33%;
p=0.016

EFS

2.53 vs 1.31 months;
HR 0.74 (95% CI 0.58, 0.96); p=0.021

quadruple_graphic

In AML-MRC and t-AML, consider
using Vyxeos Liposomal first

The American Society of Hematology (ASH) Guidelines: A Summary by Dr Priyanka Mehta

A brief summary from Dr Priyanka Mehta of the latest American Society of Hematology (ASH) recommendations for the treatment of older patients with AML.

UK-VYX-2200089 | June 2022

FOOTNOTES

* High-risk AML is defined as therapy-related AML or AML with myelodysplasia-related changes
† Defined as a diagnosis of MDS, MPN, CMML or a non-lymphoid haematological disorder recorded at least 3 months before AML diagnosis

ABBREVIATIONS

AML, acute myeloid leukaemia; AML-MRC, acute myeloid leukaemia with myelodysplasia-related changes; ASH, American Society of Hematology; CI, confidence interval; CMML, chronic myelomonocytic leukaemia; CR/CRi, complete remission/complete remission with incomplete haematological recovery; DA, daunorubicin and cytarabine; EFS, event-free survival; EHA, European Haematology Association; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; mOS, median overall survival; MPN, myeloproliferative disorder; NR, not reached; OS, overall survival; sAML, secondary acute myeloid leukaemia; t-AML, therapy-related acute myeloid leukaemia

REFERENCES
  1. Østgård LS, et al. J Clin Oncol 2015;33(31):3641–3649
  2. Lancet JE, et al. J Clin Oncol 2018;36(26):2684–2692

ADVERSE EVENTS REPORTING

Adverse events should be reported. For the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

For the Republic of Ireland, reporting forms and information can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue

Adverse events should also be reported to Jazz Pharmaceuticals by phone: +44 8081890387 (UK toll-free) or +353 1 968 1631 (Republic of Ireland).

UK-VYX-2200069 | June 2022